Overview

Everolimus (RAD001) Therapy for Epilepsy in Patients With Tuberous Sclerosis Complex (TSC)

Status:
Completed
Trial end date:
2016-04-01
Target enrollment:
Participant gender:
Summary
The goal of this study is to learn if the study drug RAD001 can reduced the number of epileptic seizures, and can be taken safety by people who have epilepsy associated with Tuberous Sclerosis Complex.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Children's Hospital Medical Center, Cincinnati
Collaborator:
Novartis
Treatments:
Everolimus
Sirolimus